NASDAQ:IDXX IDEXX Laboratories (IDXX) Stock Price, News & Analysis $696.53 +6.29 (+0.91%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About IDEXX Laboratories Stock (NASDAQ:IDXX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IDEXX Laboratories alerts:Sign Up Key Stats Today's Range$683.72▼$698.2250-Day Range$504.70▼$706.6552-Week Range$500.61▼$769.98Volume49,531 shsAverage Volume577,537 shsMarket Capitalization$54.88 billionP/E Ratio46.92Dividend YieldN/APrice Target$717.27Consensus RatingModerate Buy Company Overview IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality. Its customers include veterinary clinics, animal-health businesses and organizations responsible for water testing. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX serves customers in markets around the world. Its business has grown from a focus on veterinary diagnostics into a broader portfolio of animal-health and water-testing solutions.AI Generated. May Contain Errors. Read More IDEXX Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreIDXX MarketRank™: 2.421312349955 of 5 starsIDEXX Laboratories scored higher than 48% of companies evaluated by MarketBeat, and ranked 580th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingModerate Buy Consensus RatingIDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on no strong buy ratings, 7 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for IDEXX Laboratories is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageIDEXX Laboratories has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEXX Laboratories' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.63% Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 11.63% in the coming year, from $15.05 to $16.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 46.54, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.21.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 46.54, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 29.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IDEXX Laboratories' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.01% of the float of IDEXX Laboratories has been sold short.Short Interest Ratio / Days to CoverIDEXX Laboratories has a short interest ratio ("days to cover") of 4.45.Change versus previous monthShort interest in IDEXX Laboratories has recently increased by 22.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.42 News SentimentIDEXX Laboratories has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IDEXX Laboratories this week, compared to 6 articles on an average week.Search Interest21 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 425% compared to the previous 30 days.MarketBeat Follows4 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,567,934.00 in company stock.Percentage Held by Insiders0.79% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEXX Laboratories' insider trading history. Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXX Stock News HeadlinesIdexx Laboratories (IDXX) Stock Forecast & Price TargetNovember 11, 2026 | tipranks.comInsider Selling: IDEXX Laboratories (NASDAQ:IDXX) EVP Sells $6,132,582.54 in StockNovember 8, 2026 | americanbankingnews.comUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.November 18 at 1:00 AM | Profits Run (Ad)Insider Selling: IDEXX Laboratories (NASDAQ:IDXX) Insider Sells $17,678,196.60 in StockNovember 8, 2026 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Stock: Insider Daniel Junius Sells 1,200 SharesNovember 7, 2026 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Director Daniel Junius Sells 1,200 Shares of StockNovember 6, 2026 | insidertrades.comIDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)November 4, 2026 | seekingalpha.comIDEXX Laboratories: Q3 Results Confirm They Are Best-In-ClassNovember 4, 2026 | seekingalpha.comSee More Headlines IDXX Stock Analysis - Frequently Asked Questions How have IDXX shares performed this year? IDEXX Laboratories' stock was trading at $676.53 at the beginning of the year. Since then, IDXX shares have increased by 2.0% and is now trading at $690.24. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Monday, November, 2nd. The company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.71 by $0.25. IDEXX Laboratories's quarterly revenue was up 9.9% on a year-over-year basis. Read the conference call transcript. Who are IDEXX Laboratories' major shareholders? Top institutional investors of IDEXX Laboratories include State Street Corp (4.77%), Bamco Inc. NY (2.26%), Goldman Sachs Group Inc. (1.49%) and Montrusco Bolton Investments Inc. (0.40%). Insiders that own company stock include Jonathan Jay Mazelsky, Brian P Mckeon, Nimrata Hunt, Michael G Erickson, James F Polewaczyk, George Fennell, Sharon E Underberg, Michael Lane, Daniel M Junius, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin. View institutional ownership trends. How do I buy shares of IDEXX Laboratories? Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include NVIDIA (NVDA), Tesla (TSLA), PayPal (PYPL), Trade Desk (TTD), Salesforce (CRM), Walt Disney (DIS) and Mastercard (MA). Company Calendar Last Earnings11/02/2026Today11/18/2026Fiscal Year End12/31/2026AGM 20271/18/2027Next Earnings (Estimated)2/01/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, IDXX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:IDXX CIK874716 Webwww.idexx.com Phone(207) 556-0300Fax207-556-4346Employees11,000Year Founded1983Price Target and Rating Average Price Target for IDEXX Laboratories$717.27 High Price Target$810.00 Low Price Target$665.00 Potential Upside/Downside+3.0%Consensus RatingModerate Buy Rating Score (0-4)2.54 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$14.83 Trailing P/E Ratio46.99 Forward P/E Ratio41.47 P/E GrowthN/ANet Income$1.06 billion Net Margins25.36% Pretax Margin31.72% Return on Equity71.04% Return on Assets33.99% Debt Debt-to-Equity Ratio0.16 Current Ratio1.19 Quick Ratio0.88 Sales & Book Value Annual Sales$4.30 billion Price / Sales12.75 Cash Flow$15.00 per share Price / Cash Flow46.44 Book Value$23.73 per share Price / Book29.36Miscellaneous Outstanding Shares78,790,000Free Float78,164,000Market Cap$54.89 billion OptionableOptionable Beta1.55 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:IDXX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEXX Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.